Oncovin (Vincristine Sulfate)

Vincristine binds to β‑tubulin, inhibiting microtubule polymerization and causing depolymerization. This disrupts the mitotic spindle, arrests cells in metaphase, and leads to apoptosis of rapidly dividing cancer cells. The mechanism targets cell division without significantly affecting non‑dividing cells at therapeutic doses.

The specific dose of vincristine is determined by the prescribing oncologist based on the patient’s age, weight, disease type, and treatment protocol. Dosing is individualized and adjusted according to clinical response and tolerability, and should never be altered without medical guidance.

Vincristine is classified as pregnancy category D, indicating evidence of fetal risk. It should be avoided during pregnancy unless the potential therapeutic benefit justifies the risk. Breastfeeding is not recommended while receiving vincristine because the drug can be excreted in milk and may harm the infant.

To order Oncovin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and assistance with import documentation.

Vincristine belongs to the Vinca alkaloid class, with vinblastine being a closely related alternative. Both inhibit microtubule formation, but vincristine is generally more potent for hematologic malignancies, while vinblastine is often preferred for certain solid tumors. Choice depends on disease type, toxicity profile, and physician experience.

Oncovin should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken, and it should remain in its original packaging until use to maintain stability. Once prepared for infusion, it should be used within the time frame recommended by the manufacturer.

Oncovin is given by intravenous infusion, typically diluted in a compatible carrier solution such as normal saline or dextrose. Administration is performed by a qualified healthcare professional, often over a period of several minutes, with monitoring for infusion‑related reactions and vital signs throughout the procedure.

The most serious risks include severe peripheral neuropathy, which can be irreversible; profound neutropenia leading to infection; anaphylactic or severe allergic reactions; SIADH causing hyponatremia; and rare cardiac arrhythmias. Patients should be closely monitored for neurological changes, blood counts, and electrolyte disturbances.

Vincristine is contraindicated in individuals with known hypersensitivity to vincristine or any component of the formulation. Patients with severe hepatic impairment, uncontrolled infections, or pre‑existing severe neuropathy should avoid its use. Caution is also advised for those receiving other neurotoxic agents or with significant bone‑marrow suppression.